Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Among authors: appenteng k. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV, Linder M, Arana A, Pottegård A, Berglind IA, Bui CL, Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S, Hallas J. Margulis AV, et al. Among authors: appenteng k. PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456. eCollection 2018. PLoS One. 2018. PMID: 30260993 Free PMC article.
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries.
Heintjes EM, Bezemer ID, Prieto-Alhambra D, Smits E, Booth HP, Dedman D, He Y, Hoti F, Vehkala M, de Vogel S, Robinson NJ, Appenteng K, Penning-van Beest FJA. Heintjes EM, et al. Among authors: appenteng k. Clin Epidemiol. 2020 May 1;12:423-433. doi: 10.2147/CLEP.S242065. eCollection 2020. Clin Epidemiol. 2020. PMID: 32431551 Free PMC article.
Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom.
Arana A, Margulis AV, Varas-Lorenzo C, Bui CL, Gilsenan A, McQuay LJ, Reynolds M, Rebordosa C, Franks B, de Vogel S, Appenteng K, Perez-Gutthann S. Arana A, et al. Among authors: appenteng k. Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-247. doi: 10.1002/pds.5150. Epub 2020 Oct 28. Pharmacoepidemiol Drug Saf. 2021. PMID: 33091194 Free PMC article.
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. Phiri K, et al. Among authors: appenteng k. Curr Med Res Opin. 2021 May;37(5):867-877. doi: 10.1080/03007995.2021.1891035. Epub 2021 Mar 8. Curr Med Res Opin. 2021. PMID: 33591859
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.
de Vogel S, Seeger JD, Arana A, Margulis AV, McQuay LJ, Perez-Gutthann S, Hallas J, Kristiansen NS, Linder M, Odsbu I, Suehs B, Xu Y, Uribe C, Appenteng K, Robinson NJ. de Vogel S, et al. Among authors: appenteng k. Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5799. doi: 10.1002/pds.5799. Pharmacoepidemiol Drug Saf. 2024. PMID: 38680102 Review.
Challenges facing drug utilization research in the Latin American region.
Salas M, Lopes LC, Godman B, Truter I, Hartzema AG, Wettermark B, Fadare J, Burger JR, Appenteng K, Donneyong M, Arias A, Ankrah D, Ogunleye OO, Lubbe M, Horne L, Bernet J, Gómez-Galicia DL, Del Carmen Garcia Estrada M, Oluka MN, Massele A, Alesso L, Herrera Comoglio R, da Costa Lima E, Vilaseca C, Bergman U. Salas M, et al. Among authors: appenteng k. Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1353-1363. doi: 10.1002/pds.4989. Epub 2020 May 17. Pharmacoepidemiol Drug Saf. 2020. PMID: 32419226 Free article. Review.
49 results